PR
Perrigo
PRGO · NYSE
$14.59 -2.21% (-$0.33)
1M +15.35%
Market Cap $2.02B
P/E Ratio -
Div. Yield 7.95%
ROE 55.97%
Bulios Fair Price
$11.29
22.6% downside
Current Price
$14.59
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PRGO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
100 /100
Cheap P/S 0.49x
P/B 0.80x
P/FCF 11.54x
Growth
6 /100
Declining Rev. growth 1.51%
FCF growth 11.72%
Book val. growth 15.37%
Profitability
29 /100
Weak Gross margin 33.26%
Net margin 41.85%
FCF margin 4.22%
Quality
13 /100
Poor ROIC 3.46%
ROE 55.97%
Asset turnover 0.54x
Debt
42 /100
Moderate Debt/Equity 1.31x
Current ratio 2.32x
Int. coverage -8.89x
Stability
52 /100
Moderate Beta 0.54x
Rev. volatility 5.45%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PRGO
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Albert A. Manzone
Employees
8,100
Headquarters
Dublin
Upcoming events
04 NOV
Earnings
Upcoming earnings report